Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

This study has been completed.
Information provided by (Responsible Party):
Sumitomo Dainippon Pharma Co., Ltd. Identifier:
First received: June 6, 2012
Last updated: June 30, 2015
Last verified: June 2015
The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with schizophrenia.

Condition Intervention Phase
Drug: SM-13496 40mg
Drug: SM-13496 80mg
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Double-blind, Parallel- Group, Placebo-controlled, Confirmatory Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia <Phase 3>

Resource links provided by NLM:

Further study details as provided by Sumitomo Dainippon Pharma Co., Ltd.:

Primary Outcome Measures:
  • Change from baseline in PANSS total score [ Time Frame: Change from baseline ] [ Designated as safety issue: No ]

Enrollment: 457
Study Start Date: June 2012
Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SM-13496 40mg Drug: SM-13496 40mg
once daily orally
Experimental: SM-13496 80mg Drug: SM-13496 80mg
once daily orally
Placebo Comparator: Placebo Drug: Placebo
once daily orally


Ages Eligible for Study:   18 Years to 74 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient meets DSM-IV-TR criteria for schizophrenia.
  • Patient is aged 18 through 74 years at informed consent.
  • Patient understands the objectives, procedures, and possible benefits and risks of the study and who provide written voluntarily consent to participate in the study

Exclusion Criteria:

  • Patient has a history of neuroleptic malignant syndrome, water intoxication, or paralytic ileus.
  • Patient has Parkinson's disease.
  • Patient has a history or complication of malignancy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01614899

69 Sites
Tokyo, etc, Japan
Korea, Republic of
22 Sites
Seoul, etc, Korea, Republic of
10 Sites
Kuala Lumpur, etc, Malaysia
14 Sites
Taipei, etc, Taiwan
Sponsors and Collaborators
Sumitomo Dainippon Pharma Co., Ltd.
Study Director: Clinical Development Drug development Division Sumitomo Dainippon Pharma Co., Ltd.
  More Information

Responsible Party: Sumitomo Dainippon Pharma Co., Ltd. Identifier: NCT01614899     History of Changes
Other Study ID Numbers: D1001056  JapicCTI-121859 
Study First Received: June 6, 2012
Last Updated: June 30, 2015
Health Authority: Japan: Pharmaceuticals and Medical Devices Agency

Additional relevant MeSH terms:
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Lurasidone Hydrochloride
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
Adrenergic alpha-2 Receptor Antagonists
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Serotonin 5-HT2 Receptor Antagonists
Serotonin Antagonists
Serotonin Agents
Dopamine D2 Receptor Antagonists
Dopamine Antagonists
Dopamine Agents processed this record on October 26, 2016